Oligonucleotides packaged into virus-like particles of RNA bacteriophages
The invention provides processes for the producing compositions comprising (i) a virus-like particle, wherein said virus-like particle is a virus-like particle of an RNA bacteriophage, and (ii) an oligonucleotide, wherein said oligonucleotide is packaged into said virus-like particle. The invention further provides processes for producing nucleotide compositions comprising oligonucleotides suitable to be used in the processes mentioned before. The invention further provides nucleotide compositions obtainable by the processes of the invention and uses thereof. The invention further provides compositions comprising (i) a virus-like particle, wherein said virus-like particle is a virus-like particle of an RNA bacteriophage, and (ii) an oligonucleotide, wherein said oligonucleotide is packaged into said virus-like particle, wherein said compositions are obtainable by the processes of the invention and wherein said compositions preferably comprises a purity of at least 98%, most preferably of at least 99%.
1. A composition obtainable by a process, wherein said composition comprises
(i) a virus-like particle of an RNA bacteriophage, and
(ii) aggregated oligonucleotides, wherein said aggregated oligonucleotides comprise a relative peak start time of 50 to 110%, wherein said relative peak start time is determined in size exclusion HPLC with the capsid of an RNA bacteriophage as the standard, and wherein said oligonucleotides comprise at least one poly G stretch and are packaged into said virus-like particle,
and wherein said process comprises
(a) providing coat protein of said RNA bacteriophage;
(b) providing said aggregated oligonucleotides,
(c) generating a mixture, wherein said mixture comprises:
(i) said coat protein;
(ii) an agent capable of preventing the self-assembly of said coat protein;
(iii) said aggregated oligonucleotides;
(d) removing said agent from said mixture; and
(e) allowing said coat protein to self assemble into a virus-like particle.
2. The composition of claim 1 , wherein said RNA bacteriophage is bacteriophage Qβ.
3. The composition of claim 1 , wherein said oligonucleotides have the nucleic acid sequence “G10” GGGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:8).
4. The composition of claim 1 , wherein the purity of said composition is at least 80%.
5. The composition of claim 1 , wherein said oligonucleotides are not accessible to DNAse hydrolysis.
6. The composition of claim 1 , wherein said RNA bacteriophage is bacteriophage AP205.
7. The composition of claim 1 , wherein said oligonucleotides have the nucleic acid sequence “G8-8” GGGGGGGGGACGATCGTCGGGGGGGG (SEQ ID NO:6).
8. The composition of claim 1 , wherein said aggregated oligonucleotides comprise a relative peak start time of 80 to 110%, wherein said relative peak start time is determined in size exclusion HPLC with the capsid of an RNA bacteriophage as the standard.
9. The composition of claim 1 , wherein said coat protein comprises the sequence selected from the group consisting of:
(a) SEQ ID NO:10; and
(b) a mixture of SEQ ID NO:10 and SEQ ID NO:11.
10. The composition of claim 1 , wherein said coat protein consists of the sequence of SEQ ID NO:10.
11. The composition of claim 1 , wherein the concentration of said oligonucleotides in said mixture is 25 to 100 μM.
12. The composition of claim 1 , wherein the molar ratio of said oligonucleotides and said coat protein in said mixture is 0.5 to 1.2.
13. The composition of claim 1 , wherein said agent comprises a denaturing compound selected from urea and guanidiniumhydrochloride.
14. The composition of claim 1 , wherein said agent further comprises a reducing agent.
15. The composition of claim 1 , wherein said removing of said agent from said mixture is performed by a first buffer exchange with a first buffer, wherein said first buffer comprises sodium chloride.
16. The composition of claim 15 , wherein said first buffer exchange is performed across a membrane, wherein said membrane comprises a molecular weight cut off of 1 to 50 kD.
17. The composition of claim 1 , wherein said process further comprises the step of contacting said virus-like particle with an oxidizing agent, wherein said oxidizing agent is selected from the group consisting of:
(a) hydrogen peroxide;
(b) oxygen;
(c) gluthathion;
(d) Cu 2+ , and
(e) Fe 3+ .
18. The composition of claim 1 , wherein said process further comprises the step of purifying said virus-like particle, and wherein said purifying comprises a second buffer exchange with a second buffer, wherein said second buffer is a pharmaceutically acceptable buffer.
19. The composition of claim 18 , wherein said second buffer exchange is performed using a membrane, wherein said membrane comprises a molecular weight cut off of 100 to 1000 kD.
20. The composition of claim 1 , wherein the protein yield is at least 75% and/or wherein the oligonucleotide yield is at least 75%.